This book illustrates the significance of probiotics and prebiotics for the management of various types of cancers. The up-to-date chapters provide recent information about the effect of anticancer treatment approaches on gut microbiota, the correlation between ROS and synbiotics for effective cancer treatment, and the influence of synbiotics on inflammation and immune microenvironment for cancer treatment. It also describes the regulatory issues about synbiotics in the management of cancer. This book is an essential resource for scientists working in the field of cancer, pharmaceutical & clinical sciences, and cancer clinicians. This book is also very useful for undergraduate and postgraduate students of Pharmacy and Biotechnology and medical researchers, mainly working in microbiology, immunology, and cancer biology.
Dr. Neeraj Mishra is working as Professor in Amity Institute of Pharmacy, Gwalior since July 2019. Has done his M Pharm and Ph.D. in Pharmaceutics from Dr. H.S. Gour Central University, Sagar (M.P.), India. He is having around twenty years teaching and research experience. He is having around 100 publications of International and National repute in recent concept of novel drug delivery system, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for treatment of breast, colon cancer and neurodegenerative disorders. Dr. Mishra is having total citation 2750; h- index 25 and i- index 32. The total cumulative Impact Factor of his published papers is around 300 (as per SCOPUS). He is also written 5 Books and 9 book chapter in national and international publisher. He has also published 3 International and 3 National patents. Dr. Mishra has also received “Distinguished Professor Award” 2019, from DST- SPAICS in the workshop held at Smriti College of Pharmaceutical Education and Research, M.P., India. Recently, Dr. Mishra has received “Distinguished Professor Award” 2021 from IPA, MP State Branch, Indore. He also served as Guest Editor of Thematic issue entitled “Nanoparticulate Carriers for the treatment of Infectious Diseases and Cancer”, Current Molecular Pharmacology, Volume 14, 2021, Issue number 3, Bentham Sciences, USA.
Dr. Shvetank Bhatt is currently working as an Associate Professor in School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India. He has done M.Pharm in Pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka and Ph.D. in Neuropharmacology from Birla Institute of Technology & Science (BITS) Pilani, Pilani Campus, Rajasthan. He has total 16 years of industrial and academic research experience. His are of specialization is CNS disorders, pain, inflammation and immunooncology. He is recipient of Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award (Best Paper in Pharmacology-IJPER) in 2012 and 2014. He has published more than 80 papers in various journals of national and international repute. Dr. Bhatt is having total citation 750; h- index 14 and i- index 24. The total cumulative Impact Factor of his published papers is around 140 (as per SCOPUS). He is life member of Association of Pharmaceutical Teachers of India (APTI) and Indian Pharmacological Society (IPS).
Dr. Keshav Raj Paudel is an IASLC early career researcher at the Centre for Inflammation, Centenary Institute/UTS. He completed his Ph.D. (2017) from Mokpo National University, South Korea, and started his first postdoctoral research at the University of Texas Health Science Centre at Houston Texas, USA-2018 on an NIH-funded project. He is an emerging scientist with a good scientific track record demonstrated through his publications and successful grants. After joining UTS in 2019 for a second postdoctoral position, his research trajectory is continuously upraising in the field of translational research with a major focus on pulmonary diseases. As an early career researcher, he is currently leading various in vitro and in vivo projects under the supervision of Prof. Philip Hansbro with his research expertise, to investigate the potential of nano^ $585K) including IASLC ECR fellowship-2019 (lead CI), TSANZ-grant-in-aid-2021 (lead CI), SPHERE seed grant-2020 (co-CI), Triple I- seed grant (co-CI) and UTS seed grant-2021 (co-CI). Since 2015, he has published more than 100 peer-reviewed scientific articles and book chapters (> 50% as first/senior author in leading journals such as European Respiratory Journal, Cell Death and Diseases, Cell reports, Journal of Controlled Release, Medical Journal of Australia, Drug Discover Today, and Antioxidants, with total citation >1800. He is also a journal reviewer of more than 50 journals and has already reviewed more than 140 research papers. As a journal editor, he has handled more than 40 papers so far from Frontiers in Medicine, Frontiers in Pharmacology, Antioxidants, Journal of Immunology Research, Oxidative Medicine and Cellular Longevity Heliyon.
Prof Philip M Hansbro is Director, Centre for inflammation, Centenary Institute/UTS, NHMRC Level 2 Investigator & Conjoint Prof Research Centre for Healthy Lungs Hunter Medical Research Inst/Uni Newcastle. He built & leads an internationally renowned group that investigates the pathogenesis of respiratory diseases (asthma, COPD, IPF, respiratory infections, lung cancer). He has extensive expertise in developing/using mouse models that recapitulate the major features of human disease & state-of-the-art mouse research facilities (incl PC3 for COVI^400 publications; ~40% as senior author in high impact journals: ~4,000 citations/year.
Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
